Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott(Beth Israel Deaconess Medical Center), Michael B. Atkins(Georgetown University), Julie R. Brahmer(Johns Hopkins University), Vindira Sankar(Bristol-Myers Squibb (Germany)), Charles G. Drake(Columbia University Irving Medical Center), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Toni K. Choueiri(Harvard University), Suzanne L. Topalian(Bloomberg (United States)), Drew M. Pardoll(Bloomberg (United States)), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Dan McDonald(Johns Hopkins University), Georgia Kollia(Bristol-Myers Squibb (United States)), F. Stephen Hodi(Harvard University), Richard D. Carvajal(Northwell Health), John D. Powderly(Carolina BioOncology Institute), Hans J. Hammers(Southwestern Medical Center), Ashok Gupta, Harriet M. Kluger(Yale Cancer Center), David C. Smith(University of Michigan), Mario Sznol(Yale University)
Cited by 443
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k